Table 5.

Identification and characterization of ex vivo CMV, PR1, and WT1 tetramer-positive CD3+CD8+ T cells in healthy donors and patients with CML

% tetramer-positive CD8+ T cells
UPN
Tetramer (%)
Central memory
Effector memory
283, before SCT   CMV (3.2)   23   77  
210, after SCT   CMV (1.81)   18   82  
210, before SCT   PR1 (0.17)   64   36  
210, before SCT   WT1 (0.12)   70   30  
283, before SCT   PR1 (0.16)   64   36  
319, after SCT   PR1 (0.45)   56   44  
319, after SCT   WT1 (0.07)   59   41  
210, after SCT   PR1 (0.15)   58   43  
2, healthy donor   PR1 (0.13)   63   37  
12, healthy donor
 		 WT1 (0.056)
 		 75
 		 25
 
% tetramer-positive CD8+ T cells
UPN
Tetramer (%)
Central memory
Effector memory
283, before SCT   CMV (3.2)   23   77  
210, after SCT   CMV (1.81)   18   82  
210, before SCT   PR1 (0.17)   64   36  
210, before SCT   WT1 (0.12)   70   30  
283, before SCT   PR1 (0.16)   64   36  
319, after SCT   PR1 (0.45)   56   44  
319, after SCT   WT1 (0.07)   59   41  
210, after SCT   PR1 (0.15)   58   43  
2, healthy donor   PR1 (0.13)   63   37  
12, healthy donor
 		 WT1 (0.056)
 		 75
 		 25
 
View Large